In a filing, Bionano Genomics Inc. revealed its Director Linney Yvonne unloaded Company’s shares for reported $72402.0 on Aug 15. In the deal valued at $3.62 per share,20,000 shares were sold. As a result of this transaction, Linney Yvonne now holds 0 shares worth roughly $ 0.0.
Then, BARKER DAVID L bought 10,000 shares, generating $16,000 in total proceeds. Upon buying the shares at $1.60, the Director now owns 13,894 shares.
Scotiabank initiated its Bionano Genomics Inc. [BNGO] rating to a Sector outperform in a research note published on Tuesday, January 05, 2023; the price target was $4. PT values the company’s stock at a premium of 54.0 to its Tuesday closing price. BTIG Research started covering the stock on June 16, 2021. It rated BNGO as “a Buy”.
Price Performance Review of BNGO
On Tuesday, Bionano Genomics Inc. [NASDAQ:BNGO] saw its stock fall -4.17% to $1.84. On the same session, the stock had its day’s lowest price of $1.81, but rose to a high of $1.94. Over the last five days, the stock has lost -5.64%. Bionano Genomics Inc. shares have risen nearly 26.03% since the year began. Nevertheless, the stocks have fallen -14.42% over the past one year. While a 52-week high of $4.35 was reached on 01/18/23, a 52-week low of $1.16 was recorded on 01/06/23. SMA at 50 days reached $1.9448, while 200 days put it at $1.9725. A total of 7.76 million shares were traded, compared to the trading of 5.37 million shares in the previous session.
Levels Of Support And Resistance For BNGO Stock
The 24-hour chart illustrates a support level at 1.7867, which if violated will result in even more drops to 1.7333. On the upside, there is a resistance level at 1.9167. A further resistance level may holdings at 1.9933. The Relative Strength Index (RSI) on the 14-day chart is 52.98, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.1405, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 22.95%. Stochastics %K at 80.87% indicates the stock is a selling.
How much short interest is there in Bionano Genomics Inc.?
A steep rise in short interest was recorded in Bionano Genomics Inc. stocks on Oct 13, 2022, growing by 5.74 million shares to a total of 46.73 million shares. Yahoo Finance data shows the prior-month short interest on Sep 14, 2022 was 40.99 million shares. There was a rise of 12.28%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 16.11% of the overall stock float, the days-to-cover ratio (short ratio) rose to 8.15.
Bionano Genomics Inc. [BNGO] – Who Are The Largest Shareholders?
In filings from BlackRock Fund Advisors, it is revealed that the company now owns 18,331,341 shares, or roughly 6.17% of the outstanding BNGO shares. In other words, the investor’s shares have risen by 536,383 from its previous 13-F filing of 17794958.0. Additionally, The Vanguard Group, Inc. increased 0.96% of its stake after which the total value it holdings stand at $22,357,644, while SSgA Funds Management, Inc. added 12.68% of its stake to hold $13.84 million in the firm. Over the last quarter, Geode Capital Management LLC purchased 108,728 shares of Bionano Genomics Inc., while Morgan Stanley & Co. LLC bought 216,838 shares. At present, Northern Trust Investments, Inc. is holding 2,578,903 shares valued at $3.77 million. Charles Schwab Investment Managem owned 2,119,628 shares of the company at the time of its most recent 13F filing, worth $3.09 million.
According to FactSet, Bionano Genomics Inc.’s share price will average $6.70 in the next year, based on opinions of analysts polled by the firm. This is up nearly 212.5 percent from its previous closing price of $1.92. Analysts expect Bionano Genomics Inc. stock to reach the higher price of $12.00, while the lowest price estimate is $3.50. However, 5 analysts have rated BNGO stock as a Buy in their predictions for 2023. The most recent change occurred on September 24, 2020 when Ladenburg Thalmann began covering the stock and recommended ‘”a Buy”‘ rating along with a $1.25 price target.